In situ bioproduction of recombinant erythropoietin in patients with chronic kidney failure, delivery of monoclonal antibodies to treat chronic immune diseases and enzyme replacement therapy are just a few of the possibilities62,63. This evidence concerns the gene EPO and chronic renal failure syndrome.